Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2025
Reporting Period: Third quarter ended September 30, 2025
Context: The filing serves to announce the issuance of a press release containing financial results and a business update for the third quarter of 2025. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document referencing a press release (Exhibit 99.1) but does not contain specific numerical data. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only confirms that a press release containing these results was issued on November 12, 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company announced a business update and scheduled a conference call to discuss the third-quarter results. Specific commentary is contained within the referenced press release (Exhibit 99.1), not the 8-K body text.
Legal Disclaimer: The information furnished in this Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. It will not be incorporated by reference into other filings unless expressly stated.
Risks: The filing explicitly states that the furnishing of this information does not constitute a determination that the information is material or complete, nor does it imply that investors should consider this information before making an investment decision.
Investor Verification Checklist
- Review Exhibit 99.1 (the Press Release dated November 12, 2025) for actual financial figures, as they are absent from the 8-K summary text.
- Verify the details of the conference call mentioned in the press release to hear management's direct commentary on the Q3 2025 results.
- Confirm the liquidity position and cash runway, as the 8-K does not disclose current cash balances or debt obligations.
- Check for any subsequent filings (e.g., 10-Q) that may provide audited or reviewed financial statements for the period ended September 30, 2025.